Abirakast 250mg Tablet

Prostate Cancer

Like any other anticancer medicine, Abirakast 250mg Tablet also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:
Diarrhea
High blood pressure
Cough
Joint swelling
Nausea
Hot flashes
Headache
Increased glucose level in the blood
Edema (swelling)
Vomiting
Decreased potassium level in the blood
Fatigue
Anemia (low number of red blood cells)
Urinary tract infection
Seek medical attention in case of any unusual or severe side effects immediately.

Take Abirakast 250mg Tablet in the dosage and duration exactly as prescribed by the doctor. The medicine should be taken orally on an empty stomach or can be consumed one hour before or two hours after a meal. In case of an overdose, contact your doctor immediately.

Abirakast 250mg Tablet is an anticancer medicine prescribed to treat prostate cancer. It works by blocking the action of CYP17 enzyme to stop the production of male hormones that are responsible for the prostate cancer. In this way it slow down or stop the uncontrolled growth of cancer cells effectively.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

1.Flaig, T. W., Plets, M., Hussain, M. H., Agarwal, N., Mitsiades, N., Deshpande, H. A., ... & Thompson, I. M. (2017). Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction. JAMA oncology, 3(11), e170231-e170231.
2.Chi, K. N., Spratlin, J., Kollmannsberger, C., North, S., Pankras, C., Gonzalez, M., ... & Tran, N. P. (2015). Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer. The Journal of Clinical Pharmacology, 55(12), 1406-1414.
3.Shah, S., & Ryan, C. J. (2009). Abiraterone acetate. Drugs of the Future, 34(11).
4.Gonçalves, B. F., de Campos, S. G. P., Fávaro, W. J., Brandt, J. Z., Pinho, C. F., Justulin, L. A., ... & Scarano, W. R. (2018). Combinatorial effect of abiraterone acetate and NVP-BEZ235 on prostate tumor progression in rats. Hormones and Cancer, 9(3), 175-187.
5. Taheri, A., Almasri, R., Wignall, A., Schultz, H. B., Elz, A. S., Ariaee, A., ... & Prestidge, C. A. (2024). Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: addressing solubility and food effect challenges. Drug Delivery and Translational Research, 1-13.